Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, non-Hodgkin's lymphoma, especially aggressive types like diffuse large B-cell lymphoma, represents a significant health burden. CAR T-Cell therapy is emerging as a potential cure, achieving over 50% complete response rates in clinical trials. The market's growth is further supported by FDA-approved therapies such as Yescarta, Kymriah, and Breyanzi, and a focus on next-generation CAR T innovations, including dual-targeted and allogeneic platforms. Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global CAR T-Cell therapy market for non-hodgkin's lymphoma (NHL) is witnessing a robust expansion, driven by a convergence of clinical innovation, rising dis
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]Seeking Alpha
- Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewswire
- Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual MeetingGlobeNewswire
- Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business UpdateGlobeNewswire
ALLO
Earnings
- 11/6/25 - Beat
ALLO
Sec Filings
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- 11/13/25 - Form SCHEDULE
- ALLO's page on the SEC website